CDRH Clinical Study Service Contract

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

75F40126Q00193

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

R425

Additional Details
Set Aside

NONE

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
Documents5
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a Combined Synopsis/Solicitation for the "CDRH Clinical Study Service Contract." This procurement seeks to engage qualified vendors to provide specialized clinical study services in support of the Center for Devices and Radiological Health (CDRH). The contract is intended to facilitate research and development activities within the physical, engineering, and life sciences domains, excluding nanotechnology and biotechnology, as classified under NAICS code 541715. The scope of this procurement encompasses comprehensive clinical study services, with the objective of advancing the FDA’s mission to ensure the safety and effectiveness of medical devices and radiological health products. While the specific requirements and deliverables are detailed in the attached Request for Quotation (RFQ), contractors can anticipate that the engagement will involve supporting clinical research initiatives, data collection and analysis, and potentially contributing to regulatory science efforts that inform public health decisions. The place of performance for this contract is Silver Spring, Maryland, reflecting the location of the CDRH and the FDA’s Office of Acquisition and Grant Services. The procurement is classified under Product Service Code R425, which pertains to professional and technical support services, further emphasizing the need for expertise in clinical study management and scientific research support. This opportunity is not set aside for any specific small business or socioeconomic category, indicating that all qualified vendors, regardless of size, are eligible to compete. The procurement is being managed by the FDA’s Office of Acquisition and Grant Services, with primary and secondary points of contact provided for inquiries: Natalie Brown ([email protected]) and Ian Weiss ([email protected], 301-796-5728). Interested contractors should review the attached RFQ for detailed requirements and submission instructions. The solicitation is currently active, with responses due by August 4, 2026, at 18:08. All correspondence and submissions should reference Procurement Identifier 75F40126Q00193 and the SAM.gov Opportunity ID 420292edca5d42d6846991bb637d67fd. This procurement represents a significant opportunity for organizations with demonstrated capabilities in clinical research and development within the life sciences sector to support the FDA’s critical public health mission. Contractors are encouraged to assess the alignment of their expertise and resources with the stated objectives and to contact the designated representatives for any clarifications prior to the submission deadline.